Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008457 | 0.89 | POLB (0.46) | PKMPOLBTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL15707100 | 0.89 | POLB (0.46) | PKMPOLBTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL1007721 | 0.89 | POLB (0.46) | PKMPOLBTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL29391873 | 0.84 | ALDH1A1 (0.37) | PKMKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL21088981 | 0.82 | POLB (0.50) | PKMPOLBTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL11927511 | 0.82 | ALDH1A1 (0.36) | PKMSMN1; SMN2ALDH1A1CARM1PRMT6 | |
| SCHEMBL12336352 | 0.82 | HSD17B10 (0.44) | PKMSMN1; SMN2SFRP1ALDH1A1HTT | |
| SCHEMBL16690690 | 0.81 | KDM4E (0.33) | PKMPOLBTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL17207600 | 0.81 | CYP11B2 (0.41) | TSHRKDM4EALDH1A1HTTKMT2A | |
| SCHEMBL19080601 | 0.80 | POLB (0.44) | PKMPOLBTSHRKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | PKM 401/4885POLB 931/4885TSHR 2714/4885 |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | PKM 2217/4885POLB 3442/4885TSHR 422/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | PKM 2981/4885POLB 1471/4885TSHR 819/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | PKM 1061/4885POLB 3203/4885TSHR 3341/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | PKM 2217/4885POLB 3442/4885TSHR 422/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | PKM 2991/4885POLB 1260/4885TSHR 727/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | PKM 2398/4885POLB 1950/4885TSHR 716/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | PKM 2446/4885POLB 2282/4885TSHR 1425/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | PKM 2427/4885POLB 1542/4885TSHR 881/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | PKM 1061/4885POLB 3203/4885TSHR 3341/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | PKM 2217/4885POLB 3442/4885TSHR 422/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | PKM 2217/4885POLB 3442/4885TSHR 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.